UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 74

Sortiert nach

Safety and pharmacokinetics of anti‐TFPI antibody (concizumab) in healthy volunteers and patients with hemophilia: a randomized first human dose trial

Journal of thrombosis and haemostasis, 2015-05, Vol.13 (5), p.743-754

2015

Link zum Volltext

Verfügbarkeit prüfen

A randomized trial of safety, pharmacokinetics and pharmacodynamics of concizumab in people with hemophilia A

Journal of thrombosis and haemostasis, 2018-11, Vol.16 (11), p.2184-2195

2018

Link zum Volltext

Verfügbarkeit prüfen

Pregnancy-associated acquired haemophilia A: results from the European Acquired Haemophilia (EACH2) registry

BJOG : an international journal of obstetrics and gynaecology, 2012-11, Vol.119 (12), p.1529-1537

2012

Link zum Volltext

Verfügbarkeit prüfen

OUTCOMES OF PATIENTS WITH WORSENING ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA (TTP) DESPITE DAILY THERAPEUTIC PLASMA EXCHANGE IN THE PHASE 3 HERCULES TRIAL

Hematology, Transfusion and Cell Therapy, 2020-11, Vol.42, p.95-95

2020

Link zum Volltext

Verfügbarkeit prüfen

Inhibition of tissue factor pathway inhibitor by the aptamer BAX499 improves clotting of hemophilic blood and plasma

Journal of thrombosis and haemostasis, 2012-08, Vol.10 (8), p.1581-1590

2012

Link zum Volltext

Verfügbarkeit prüfen

The Nationwide Austrian Aspergillus Registry: a prospective data collection on epidemiology, therapy and outcome of invasive mould infections in immunocompromised and/or immunosuppressed patients

International journal of antimicrobial agents, 2010-12, Vol.36 (6), p.531-536

2010

Link zum Volltext

Verfügbarkeit prüfen

PB2305: EFGARTIGIMOD: CLINICAL DEVELOPMENT OF A NOVEL FCRN ANTAGONIST IN THE TREATMENT OF AUTOIMMUNE DISEASES

HemaSphere, 2022-06, Vol.6 (Suppl), p.2175-2176

2022

Link zum Volltext

Verfügbarkeit prüfen

TREATMENT BURDEN AND PATIENT PREFERENCE IN PATIENTS WITH HEMOPHILIA A OR B WITH INHIBITORS ON CONCIZUMAB PROPHYLAXIS: RESULTS FROM THE PHASE 3 EXPLORER7 STUDY

Hematology, Transfusion and Cell Therapy, 2023-10, Vol.45, p.S458-S459

2023

Link zum Volltext

Verfügbarkeit prüfen

Postoperative paraneoplastic factor VIII auto-antibodies in patients with solid tumours

Haemophilia : the official journal of the World Federation of Hemophilia, 2011-09, Vol.17 (5), p.e889-e894

2011

Link zum Volltext

Verfügbarkeit prüfen

Caplacizumab induces fast and durable platelet count responses with improved time to complete remission and recurrence-free survival in patients with acquired thrombotic thrombocytopenic purpura

Hematology, Transfusion and Cell Therapy, 2020-10, Vol.42, p.62-63

2020

Link zum Volltext

Verfügbarkeit prüfen

Safety of caplacizumab in patients without documented severe adamts13 deficiency during the hercules study

Hematology, Transfusion and Cell Therapy, 2020-10, Vol.42, p.62-62

2020

Link zum Volltext

Verfügbarkeit prüfen

Comparison of enoxaparin and unfractionated heparin in endovascular interventions for the treatment of peripheral arterial occlusive disease: a randomized controlled trial

Journal of thrombosis and haemostasis, 2011-11, Vol.9 (11), p.2159-2167

2011

Link zum Volltext

Verfügbarkeit prüfen

Caplacizumab reduces the frequency of major thromboembolic events, exacerbations and death in patients with acquired thrombotic thrombocytopenic purpura

Journal of thrombosis and haemostasis, 2017-07, Vol.15 (7), p.1448-1452

2017

Link zum Volltext

Verfügbarkeit prüfen

Demographic and clinical data in acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2)

Journal of thrombosis and haemostasis, 2012-04, Vol.10 (4), p.622-631

2012

Link zum Volltext

Verfügbarkeit prüfen

OC 14.5 Plasma Exchange-free Management of Immune Thrombotic Thrombocytopenic Purpura: The Austrian-German Experience

Research and practice in thrombosis and haemostasis, 2023-10, Vol.7, p.100532, Article 100532

2023

Link zum Volltext

Verfügbarkeit prüfen

Consensus statement for cancer patients requiring intensive care support

Annals of hematology, 2018-07, Vol.97 (7), p.1271-1282

2018

Link zum Volltext

Verfügbarkeit prüfen

High proportion of patients with bleeding of unknown cause in persons with a mild‐to‐moderate bleeding tendency: Results from the Vienna Bleeding Biobank (VIBB)

Haemophilia : the official journal of the World Federation of Hemophilia, 2018-05, Vol.24 (3), p.405-413

2018

Link zum Volltext

Verfügbarkeit prüfen

NET untangled in TMA?

Journal of thrombosis and haemostasis, 2015-05, Vol.13 (5), p.729-731

Knobl, P

2015

Link zum Volltext

Verfügbarkeit prüfen

OC 14.4 Recombinant ADAMTS13 Prophylaxis in Patients with Congenital Thrombotic Thrombocytopenic Purpura: Interim Analysis from Phase 3B Continuation Study

Research and practice in thrombosis and haemostasis, 2023-10, Vol.7, p.100534, Article 100534

2023

Link zum Volltext

Verfügbarkeit prüfen

Diagnostic and prognostic value of factor VIII binding antibodies in acquired hemophilia A: data from the GTH‐AH 01/2010 study

Journal of thrombosis and haemostasis, 2016-05, Vol.14 (5), p.940-947

2016

Link zum Volltext

Verfügbarkeit prüfen

Recombinant ADAMTS13 normalizes von Willebrand factor‐cleaving activity in plasma of acquired TTP patients by overriding inhibitory antibodies

Journal of thrombosis and haemostasis, 2011-05, Vol.9 (5), p.936-944

2011

Link zum Volltext

Verfügbarkeit prüfen

LONGER-TERM CONCIZUMAB PROPHYLAXIS IN PATIENTS WITH HAEMOPHILIA A OR B WITH INHIBITORS: ≥1-YEAR (56-WEEK CUT-OFF) EFFICACY AND SAFETY RESULTS FROM THE PHASE 3 EXPLORER7 TRIAL

HAEMOPHILIA, 2023, Vol.29, p.99

2023

Link zum Volltext

Verfügbarkeit prüfen

Pharmacodynamic Profile of a Recombinant ADAMTS13 (BAX930) in Hereditary Thrombotic Thrombocytopenic Purpura (Upshaw-Schulman Syndrome (USS))

Blood, 2016-12, Vol.128 (22), p.135-135

2016

Link zum Volltext

Verfügbarkeit prüfen

LB 01.2 Emicizumab Prophylaxis Instead of Immunosuppressive Therapy in Patients with Acquired Hemophilia A (AHA)

Research and practice in thrombosis and haemostasis, 2023-10, Vol.7, p.100289, Article 100289

2023

Link zum Volltext

Verfügbarkeit prüfen

Treatment of thrombotic microangiopathy with a focus on new treatment options

Hämostaseologie, 2013-05, Vol.33 (2), p.149

Knöbl, P N

2013

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 74

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(68)
Mit Volltextzugriff
(60)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(52)
Science & Technology
(52)
Humans
(39)
Hematology
(30)
Female
(26)
Male
(26)
Middle Aged
(24)
Adult
(21)
Aged
(19)
Biological And Medical Sciences
(19)
Cardiovascular System & Cardiology
(19)
Peripheral Vascular Disease
(18)
Medical Sciences
(17)
Treatment Outcome
(15)
Hematologic And Hematopoietic Diseases
(10)
Animals
(9)
Young Adult
(8)
Adolescent
(7)
Medicin Och Hälsovetenskap
(7)
Oncology
(7)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Safety and pharmacokinetics of anti‐TFPI antibody (concizumab) in healthy volunteers and patients with hemophilia: a randomized first human dose trial

A randomized trial of safety, pharmacokinetics and pharmacodynamics of concizumab in people with hemophilia A

Pregnancy-associated acquired haemophilia A: results from the European Acquired Haemophilia (EACH2) registry

OUTCOMES OF PATIENTS WITH WORSENING ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA (TTP) DESPITE DAILY THERAPEUTIC PLASMA EXCHANGE IN THE PHASE 3 HERCULES TRIAL

Inhibition of tissue factor pathway inhibitor by the aptamer BAX499 improves clotting of hemophilic blood and plasma

The Nationwide Austrian Aspergillus Registry: a prospective data collection on epidemiology, therapy and outcome of invasive mould infections in immunocompromised and/or immunosuppressed patients

PB2305: EFGARTIGIMOD: CLINICAL DEVELOPMENT OF A NOVEL FCRN ANTAGONIST IN THE TREATMENT OF AUTOIMMUNE DISEASES

TREATMENT BURDEN AND PATIENT PREFERENCE IN PATIENTS WITH HEMOPHILIA A OR B WITH INHIBITORS ON CONCIZUMAB PROPHYLAXIS: RESULTS FROM THE PHASE 3 EXPLORER7 STUDY

Postoperative paraneoplastic factor VIII auto-antibodies in patients with solid tumours

Caplacizumab induces fast and durable platelet count responses with improved time to complete remission and recurrence-free survival in patients with acquired thrombotic thrombocytopenic purpura

Safety of caplacizumab in patients without documented severe adamts13 deficiency during the hercules study

Comparison of enoxaparin and unfractionated heparin in endovascular interventions for the treatment of peripheral arterial occlusive disease: a randomized controlled trial

Caplacizumab reduces the frequency of major thromboembolic events, exacerbations and death in patients with acquired thrombotic thrombocytopenic purpura

Demographic and clinical data in acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2)

OC 14.5 Plasma Exchange-free Management of Immune Thrombotic Thrombocytopenic Purpura: The Austrian-German Experience

Consensus statement for cancer patients requiring intensive care support

High proportion of patients with bleeding of unknown cause in persons with a mild‐to‐moderate bleeding tendency: Results from the Vienna Bleeding Biobank (VIBB)

NET untangled in TMA?

OC 14.4 Recombinant ADAMTS13 Prophylaxis in Patients with Congenital Thrombotic Thrombocytopenic Purpura: Interim Analysis from Phase 3B Continuation Study

Diagnostic and prognostic value of factor VIII binding antibodies in acquired hemophilia A: data from the GTH‐AH 01/2010 study

Recombinant ADAMTS13 normalizes von Willebrand factor‐cleaving activity in plasma of acquired TTP patients by overriding inhibitory antibodies

LONGER-TERM CONCIZUMAB PROPHYLAXIS IN PATIENTS WITH HAEMOPHILIA A OR B WITH INHIBITORS: ≥1-YEAR (56-WEEK CUT-OFF) EFFICACY AND SAFETY RESULTS FROM THE PHASE 3 EXPLORER7 TRIAL

Pharmacodynamic Profile of a Recombinant ADAMTS13 (BAX930) in Hereditary Thrombotic Thrombocytopenic Purpura (Upshaw-Schulman Syndrome (USS))

LB 01.2 Emicizumab Prophylaxis Instead of Immunosuppressive Therapy in Patients with Acquired Hemophilia A (AHA)

Treatment of thrombotic microangiopathy with a focus on new treatment options

Suchergebnisse filtern